BUDAPEST, Hungary and TOKYO, Japan, September 5 /PRNewswire/ --
ChemAxon and Teijin Pharma Ltd. announced the acquisition of ChemAxon's
database structure management and search toolkits and the switch over of
Teijin Pharma's chemical information platform to operate with ChemAxon's
The provision will see Teijin Pharma, a medical and pharmaceuticals
business subsidiary of Teijin, update their existing system for archiving
small molecules by implementing the JChem platform. The JChem platform will
better enable Teijin to develop more powerful solutions for Teijin's
research activities worldwide. The adoption of the JChem platform for small
molecule storage and search constitutes a step forward in this process.
"We are pleased with the performance and potential of the JChem tools
in our system, the functions are particularly suitable for distributed,
enterprise class solutions," commented Dr. Hiroshi Kawabata, Ph.D., Senior
Manager, Medicinal Chemistry Research Department, Pharmaceutical Discovery
Research Laboratories at Teijin Pharma Limited.
"We are very happy that our science and functionality is relevant to
Teijin, particularly given its scale and scope. Commercially we believe
that this switch may fully open the door for further adoptions in Japan and
would mirror our experience with clients globally," commented Dr Ferenc
Csizmadia, CEO of ChemAxon.
ChemAxon is a leader in providing cheminformatics software development
platforms and applications for the biotechnology, pharmaceutical and
agrochemical industries. With core capabilities for structure
visualization, search and management, property prediction, virtual
synthesis, screening and drug design, ChemAxon focuses upon active
interaction with users and software portability to create powerful, cost
effective cross platform solutions and programming interfaces to power
modern cheminformatics and chemical communication. For more information
About Teijin Group and its Pharmaceutical subsidiary
The Teijin Group (http://www.teijin.co.jp/english/flash.html) is active
in a wide range of businesses, including fibers, films, plastics,
pharmaceuticals and home health care and information technology
Teijin Pharma (http://www.teijin-pharma.co.jp/english/index.html),
medical and pharmaceuticals business subsidiary of Teijin, focuses on the
three key therapeutic areas: respiratory, bone/joint, and
cardiovascular/metabolic diseases. In the respiratory field, Teijin Pharma
has strong R&D and marketing position with pharmaceutical products and home
oxygen therapy (HOT) business, which has a top market share in Japan.
Teijin Pharma is now trying to expand its product pipeline for COPD/asthma
by in-licensing as well as in-house R&D; it will continue to pursue
providing total health care services for these patients through synergistic
activities in the pharmaceuticals and HOT businesses.
SOURCE ChemAxon Ltd.